Cullinan Oncology sets IPO terms for Nasdaq debut
January 5, 2021- Share:
Cullinan Oncology, a clinical-stage developer of cancer treatments, has established a price range of $17 to $19 per share for its upcoming offering of 8.33 million shares, according to an SEC filing. A midpoint pricing would raise nearly $150 million and value the Massachusetts-based company at about $681 million. Cullinan is backed by investors including UBS Oncology Impact Fund (25.5% pre-IPO stake) and F2 Ventures (19.5%). It plans to trade on the Nasdaq under the symbol CGEM.
- Share:
-
-
-
-